X

Drug Profile

IMM ONC 01

Alternative Names: IMM 20320 -; IMM-ONC-01

Latest Information Update: 29 May 2023

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Immunome
Class Antibodies; Antineoplastics; Immunotherapies
Mechanism of Action Interleukin receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Solid tumours

Most Recent Events

23 May 2023 Pharmacodynamics data from a preclinical trial in Solid tumours released by Immunome
14 Nov 2022 Immunome plans to file IND application for Cancer (Parenteral) in mid-2023
23 May 2022 Immunome collaborates with Fox Chase Cancer Center for IMM ONC 01

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com